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Abstract
Colorectal cancer (CRC) is a major cause of cancer-related deaths in much of the world. Most CRCs arise from pre-malignant
(dysplastic) lesions, such as adenomatous polyps, and current endoscopic screening approaches with white light do not
detect all dysplastic lesions. Thus, new strategies to identify such lesions, including non-polypoid lesions, are needed. We
aim to identify and validate novel peptides that specifically target dysplastic colonic epithelium in vivo. We used phage
display to identify a novel peptide that binds to dysplastic colonic mucosa in vivo in a genetically engineered mouse model
of colo-rectal tumorigenesis, based on somatic Apc (adenomatous polyposis coli) gene inactivation. Binding was confirmed
using confocal microscopy on biopsied adenomas and excised adenomas incubated with peptide ex vivo. Studies of mice
where a mutant Kras allele was somatically activated in the colon to generate hyperplastic epithelium were also performed
for comparison. Several rounds of in vivo T7 library biopanning isolated a peptide, QPIHPNNM. The fluorescent-labeled
peptide bound to dysplastic lesions on endoscopic analysis. Quantitative assessment revealed the fluorescent-labeled
peptide (target/background: 2.1760.61) binds ,2-fold greater to the colonic adenomas when compared to the control
peptide (target/background: 1.1460.15), p,0.01. The peptide did not bind to the non-dysplastic (hyperplastic) epithelium
of the Kras mice. This work is first to image fluorescence-labeled peptide binding in vivo that is specific towards colonic
dysplasia on wide-area surveillance. This finding highlights an innovative strategy for targeted detection to localize pre-
malignant lesions that can be generalized to the epithelium of hollow organs.
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Introduction
Colorectal cancer (CRC) is the second leading cause of cancer
death in the U.S. The average lifetime risk of CRC is 1 in 20
within the industrialized world, with the highest rate of incidence
being within the U.S. (approximately 142,000 new cases diagnosed
in 2010) [1,2]. Adenomatous polyps, or adenomas, appear to be
major precursors to CRC, though only a fraction of adenomas
progress to CRC. The current screening method for CRC and
adenomas uses standard white light endoscopy to detect
morphological changes and lesions in the mucosa. Average polyp
miss rates have been reported as high as 22%, with flat and
depressed lesions being the most difficult to identify with
conventional white light colonoscopy [3–7]. Furthermore, the
presence of flat dysplastic lesions in the setting of chronic
ulcerative colitis presents a significantly increased risk for the
development of frank carcinoma [8]. These statistics support the
fact that the morbidity rate from CRC could be significantly
reduced with new targeted methods of early cancer detection
based on protein expression rather than on anatomical changes.
Pre-clinical mouse models of disease provide an important tool
for studying mechanisms of disease development. It has been
established that mutations in the adenomatous polyposis coli (APC)
gene are likely to be critical events in the initiation of the majority
of adenomas and CRC [9–11]. Previously reported genetically
engineered mouse models that mimic human APC gene mutations
mainly develop adenomas in the small intestine (e.g. Apc
Min model),
rather than the distal colon, making it difficult to image the
progression of polyps in vivo using small animal endoscopy. In the
mouse model used in this study (CPC;Apc model [12]), one Apc
allele is somatically inactivated in the epithelium from the distal
ileum to the rectum. As described previously, the mice develop
between 4 to 10 adenomas in the distal colon and rectum. Of note,
the adenomas present within these mice not only develop from
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e17384somatic modification of a gene that underlies adenoma and
carcinoma development, but a subset also progresses to carcino-
ma, akin to the situation in man.
While adenomas have been shown as precursors of CRC,
hyperplastic polyps have not. The progression of an adenoma to
CRC can be attributed to accumulated genetic defects that regulate
homeostatic cell behavior. Mutant KRAS alleles have been shown to
promote tumorigenic growth in CRC cells, but do not in cases of
hyperplasia where the malignant potential is negligible [13]. In this
study, we also used another mouse model having an activated
Kras
G12D mutant allele that demonstrates hyperplastic polyp-like
features, to investigate fluorescent-labeled peptide binding to a
hyperplastic model that does not progress to carcinoma.
Peptides that bind to pre-cancerous colorectal lesions have the
potential to guide tissue biopsy [14], and such peptides can be
isolated using combinatorial phage display screening [14,15].
Although much effort has concentrated on small-molecule and
antibody ligands, peptides have advantages for in vivo use in the
gastrointestinal tract, because they can be delivered topically to
identify early molecular changes in the epithelium, where
adenomas and carcinomas originate. In addition, peptides have
minimal immunogenicity and can exhibit rapid binding kinetics
and diffuse into diseased mucosa. Phage display is a powerful
combinatorial technique for peptide discovery that uses methods
of recombinant DNA technology to generate a complex library of
peptides, often expressing up to 10
7–10
9 unique sequences, that
can bind to cell surface targets [16,17]. The DNA of candidate
phages can be recovered and sequenced, elucidating positive
binding peptides that can then be synthetically fabricated in large
quantities at relatively low cost. The T7 system has proven
effective for in vivo panning experiments identifying peptides
specific to pancreatic islet vasculature [18], breast vasculature [19],
bladder tumor cells [20], and hepatocytes [21]. Panning with
intact tissue presents additional relevant cell targets while
accounting for subtle features of the tissue microenvironment that
may affect binding [15,22–24].
Our aims here are to select peptides that preferentially bind to
adenomas in the CPC;Apc mouse model using in vivo phage display and
to demonstrate this binding in vivo using a fluorescence-label on small
animal endoscopy. After peptide selection, we aim to show that the
fluorescence-labeled peptide binds preferentially to dysplastic epithe-
lium in the CPC;Apc mice and not to non-dysplastic epithelium from
control mice or to hyperplastic colonic epithelium seen following
somatic activation of a mutant Kras allele in colonic epithelium.
Results
In vivo phage display panning isolated QPIHPNNM as a
binder to colonic dysplasia
After the first two rounds of in vivo panning, the number of
phages bound to the colonic adenomas was approximately the
same as that for the adjacent normal colon tissue (Fig. 1).
However, after clearing against normal colon and other organs,
the third round showed a 9-fold increase in the number of bound
phages to the adenomas over adjacent normal colon tissue. This
trend, though not as pronounced, continued after the fourth round
of panning. Fifty phages were selected from rounds three and four
of panning, and the DNA was sequenced. Three entire sequences
were repeated twice (NGTTSSNNQLINENNIQN, EHMYNT-
PHTYHTTMKNNK, QPIHPNNM) and four partial sequences
were repeated twice (NKLAAALE, KNYKN, TNTHN, KHT-
NN). The QPIHPNNM peptide was only found in round 3,
whereas the two full sequences and the four partial sequences were
found in both rounds 3 and 4. An advantage of the T7 phage
library system is that it does not have phage sequence
amplification bias as compared to other phage libraries [25], thus
any repeated phages were considered promising candidates. One
of the three repeated phages was less than 18 amino acids because
of the presence of a stop codon within the sequence. Using the
RELIC software, the INFO value for the three candidate phages
were calculated against a pool of phages from the initial T7 library
[26]. The INFO scores for the NGTTSSNNQLINENNIQN,
EHMYNTPHTYHTTMKNNK, and QPIHPNNM were 41.6,
45.2, and 49.1, respectively. A higher INFO score suggests a
greater probability that the phage clone identified was not by
chance. From this data, the QPIHPNNM peptide was the most
Figure 1. Titer results showing plaque forming units (pfu) for adenomas normalized to the number of phages bound to normal
colonic mucosa. After two rounds of panning, the recovered phage pool was first cleared against a homogenized mixture of organs (heart, kidney,
liver, normal colon) and subsequently cleared against normal colon tissue only. Clearing decreased the number of phage that bound to normal colon
tissue 96or 36in rounds 3 and 4, respectively. The titer was performed in triplicate.
doi:10.1371/journal.pone.0017384.g001
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synthesized for further testing.
Endoscopy and confocal microscopy revealed target
peptide binding in vivo
The in vivo endoscopy images revealed that the target peptide
(FITC-Ahx-QPIHPNNM) bound to the colonic adenomas and
provided greater fluorescence signal when compared to the control
peptide (FITC-Ahx-GGGAGGGA), Fig. 2 (Panels A–C). Further-
more, FITC-Ahx-QPIHPNNM showed minimal background
binding to adjacent non-adenomatous colon tissue during
endoscopy. Also, the FITC-Ahx-QPIHPNNM peptide did not
bind to colonic mucosa from control mice lacking the Cre
recombinase transgene (Fig. 2D) or to hyperplastic colonic
epithelial tissue found in mice with conditional activation of a
mutant Kras allele in colonic epithelium (Fig. 2E). Representative
histology for A) normal (scale bar 100 mm), B) hyperplastic (scale
bar 50 mm), and C,D) dysplastic (scale bar 200 and 50 mm,
respectively) colonic mucosa are shown in Fig. 3.
Adenomas that developed at approximately 4 cm proximal from
the anal verge of the mouse were minimally raised above the mucosal
surface, but their morphology, as observed via endoscopy, was not as
polypoid as more distal adenomas. Neither the target or control
peptide bound to the more proximal and minimally raised lesions.
The target peptide may not have bound, because the biopanning
experiments were initially performed using visible, polypoid adeno-
mas (i.e., CPC;Apc mice of 8 to 9 months of age). Data points for both
the target and control peptide on these minimally raised lesions at
4 cm were not used in data analysis, as there were few adenomas of
this kind for each peptide tested that were detected.
Quantitative analysis of peptide adsorption to distal colonic
adenomas revealed that the target peptide FITC-Ahx-
QPIHPNNM (T/B: 2.1760.61) binds ,2-fold greater to the
colonic adenomas when compared to the control peptide FITC-
Ahx-GGGAGGGA (T/B: 1.1460.15) (Fig. 4). Non-parametric
Mann-Whitney statistical analysis indicated that FITC-Ahx-
QPIHPNNM binds in significantly greater amounts to the
adenomas than FITC-Ahx-GGGAGGGA, p,0.01. T/B calcula-
tions for the FITC-Ahx-QPIHPNNM binding to the control or
hyperplastic mice was not possible.
Confocal microscopy images of biopsied adenomas collected
subsequent to peptide administration showed evidence that the
target peptide (Fig. 5A) bound more to adenomas than the control
peptide (Fig. 5B).
QPIHPNNM displayed enhanced binding to whole
adenomas ex vivo
Two adenomas visualized endoscopically ex vivo under conven-
tional white light illumination are shown in Fig. 6A. Gross analysis
of peptide binding on fluorescence revealed that the FITC-Ahx-
QPIHPNNM peptide bound to the excised adenomas more
robustly than the FITC-Ahx-GGGAGGGA control peptide
(Fig. 6B). Comparison between FITC-Ahx-QPIHPNNM and
FITC-Ahx-GGGAGGGA binding showed the target peptide
bound 2.5160.59 times greater than the control peptide for the
whole adenoma pairs analyzed.
From the ex vivo peptide binding experiment, confocal
microscopic imaging revealed that the FITC-Ahx-QPIHPNNM
candidate peptide showed increased binding to the dysplastic
crypts when compared to the FITC-Ahx-GGGAGGGA control
peptide (Fig. 6C and 6D). Minimal to no binding was found for the
FITC-Ahx-GGGAGGGA control peptide. These results further
validate preferential binding of the target peptide to the adenomas.
Histology of dysplasia and hyperplasia validated
The normal colonic epithelium from the CPC;Apc mice showed
well organized crypt morphology (Fig. 3A). The epithelium of the
hyperplastic Kras mice showed hyperplastic characteristics including
Figure 2. Images from wide-field endoscopy videos after
application of fluorescence-labeled peptides. The left and right
columns represent frames from white light and fluorescence, respec-
tively. The fluorescent labeled target peptide FITC-Ahx-QPIHPNNM
showed positive binding to (A) multiple adenomas and (B) single
adenoma in a CPC;Apc mouse. (C) The control peptide FITC-Ahx-
GGGAGGGA showed minimal binding. The target peptide also showed
minimal binding to (D) the lumen of a CPC;Apc bred mouse negative for
Cre recombinase (control litter mate) and (E) the hyperplastic
epithelium in a mutant Kras mouse model. White arrows identify
adenomas.
doi:10.1371/journal.pone.0017384.g002
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mice used in phage panning, in vivo peptide administration, ex vivo
peptide administration, and biopsies all showed dysplasia, charac-
terized by enlarged nuclei, hyperchromaticity, and distorted crypts
and was validated on histology (Fig. 3C and 3D).
Discussion
Here, we demonstrate targeted detection of colonic dysplasia in
vivo using a novel fluorescence-labeled peptide selected with phage
display methodologies. These findings highlight an innovative
strategy for localizing pre-malignant lesions within the epithelium
based on suspected alterations in protein expression rather than on
gross architectural abnormalities, and the results suggest that the
approach may have potential to enhance the diagnostic specificity
of endoscopy in the clinical setting. This work also supports the use
of genetically engineered mouse tumor models for longitudinal in
vivo imaging, allowing for repetitive studies and for each animal to
be used as its own control. Validation of the targeted approach
with fluorescence endoscopy was achieved using a mouse model
that spontaneously develops adenomas in the distal colon.
Previously developed Apc
Min mouse models demonstrate polyp
growth predominately in the small intestine, an anatomical
location that cannot be easily reached with endoscopy. Others
have generated mouse models that develop tumors in the distal
colon using implanted cancer cells [27] or adenovirus activated
mutations [28]. However, these models required surgical inter-
vention to generate polyps, and the ensuing response to injury may
have some contributing role in target alteration. Tissue targeting
peptides have the advantage of being topically applied where the
probe can be delivered in high concentrations to saturate over-
expressed dysplastic targets. Our results demonstrate that
preferential binding of molecular peptide probes towards dysplas-
tic colonic adenomas can be identified via in vivo phage panning.
Phage display panning uses an unbiased approach to select short
peptides that bind to over-expressed cell surface targets. Research
suggests that the T7 phage system possesses decreased sequence
bias compared to the M13 phage systems [25]. In the past, we
have successfully utilized phage display to identify peptide binders
to high grade dysplasia in human Barrett’s esophagus [29] and
colonic dysplasia [14] using the commercially available M13
phage system. Because the current experiment involved in vivo
panning, rather than panning on excised tissue or an established
cell line, we chose the T7 system to aid in the reduction of non-
specific binding. The T7 system provides greater diversity than the
M13 system, is extremely stable, amplifies in a few hours instead of
overnight, and can display larger peptides on its protein coat,
whereas M13 amplification methods can allow phages with better
growth abilities to take over the amplification culture which can
decrease diversity with successive rounds of panning, complicating
data analysis [30]. Knowing these benefits, the T7 system was built
and utilized in our panning procedure.
Figure 3. Representative histology from (A) normal colonic mucosa, (B) hyperplastic Kras, and (C–D) adenoma in CPC;Apc mice. C: An
advanced dysplastic adenoma .1 mm in size. D: Higher magnification (scale bar 50 mm) of dysplasia (boxed region of C) displaying enlarged nuclei,
hyperchromaticity and distorted crypts.
doi:10.1371/journal.pone.0017384.g003
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however, the objective of our study was to identify and validate a
peptide that could target the spontaneous adenomas in our mouse
model in vivo. The identified peptide could then be used to localize
the pre-malignant lesions on imaging. While a drop in peptide
specificity was not expected between rounds 3 and 4 (Fig. 1), this
dropcouldhaveresultedfromthenecessityofusingseparatemicein
each of these rounds. While adenomas arising in the CPC;Apc mice
used here, have the same genetic lesions initiating tumor
development (i.e., bi-allelic Apc defects in the adenomatous cells),
the biological factors contributing to the progressive growth of each
polyp likely varies within mice as it does in humans. The target
peptide, FITC-Ahx-QPIHPNNM, identified during in vivo biopan-
ning was found to bind to colonic adenomas approximately 2-fold
greater than a control peptide. This binding was validated in a
cohort of six mice, all demonstrating binding in vivo, displaying a
total of eighteen adenomas. In addition, ex vivo validation studies
that exhibited a similar 2-fold increase in binding of the target
peptide compared to the control peptide. The candidate peptide did
not bind to the colon epithelium in the hyperplastic Kras mice,
illustrating that the peptide is specific to dysplastic colonic mucosa.
Adenomatous polyps are thought to be precursors to CRC whereas
hyperplastic polyps are not [31,32], suggesting that the target
peptide could be binding to a cell surface target unique to dysplastic
and/or cancerous cells. Confocal microscopy verified that the target
peptide was indeed binding to the adenoma in comparison with the
control peptide in both the biopsy and ex vivo experiments. Our
initial studies used 59-FITC as a fluorescent probe, for compatibility
withourexisting endoscopyinstrument;however, the QPIHPNNM
peptide can be easily labeled with other dyes in the visible and near
infrared (NIR) spectrum, where improved image contrast is
expected from reduced tissue autofluorescence. Preliminary exper-
iments testing for QPIHPNNM binding to human surgical
specimens of colon adenomas have been performed and are
reported in Text S1 and Fig. S1.
Peptides with specific binding properties can be isolated using
phage display libraries. To our knowledge, colorectal targeting
peptides have been found using in vitro phage panning on colon
carcinoma cells (CPIEDRPMC on HT29 cells [33], HEWSYLA-
PYPWF on WiDr cells [34], and VHLGYAT on SW480 cells
[35]) and ex vivo panning on human colonic tissue (SPTKSNS [36]
and VRPMPLQ [14]); however, no colorectal targeting peptides
have been identified using methods of in vivo phage panning. In vitro
phage panning on established cell lines remove the targeted cells
from their native environment, possibly altering cell behavior. Ex
vivo panning procedures on excised human tissue have limitations
in that they must consider the homogeneity of tissue, the time
elapsed after being removed from the patient, and the assumption
that all patients over-express the same molecular target. In vivo
phage panning in a GEM model with genetically identical mice
can offer the advantage of isolating peptides that directly
accumulate into tumor tissue, binding to either endothelial cells
within tumor vasculature [37], epithelial cells through extravasa-
tion [38], or extracellular matrix. Work published using the fuse5
phage system show phages accumulate into normal CF-1 mouse
intestine within 1 hour post injection [39]. Taking into account
that phages are capable of extravasation within an hour and that
tumor vasculature is more porous than normal tissue, a stringent
time point of 10 minutes was used for in vivo circulation within the
CPC;Apc mouse model to isolate phages that first bind to the target
tissue. Our current work supports that phage can extravasate to
extracellular matrix and epithelial cells, determining upfront the
peptides that would be efficacious systemic tumor-targeting agents.
The previously reported peptide VRPMPLQ is a 7-mer peptide
that was isolated using human colon tissue with the intent of direct
translation of the peptide to the clinic [14], while the currently
reported QPIHPNNM peptide is an 8-mer peptide isolated using
the spontaneous mouse model (CPC;Apc) in an attempt to further
understand the mechanism of CRC. This GEM model allows
longitudinal studies to be performed, decreasing the number of
Figure 4. Quantitative analysis of peptide adsorption to distal colonic adenomas showing target peptide FITC-Ahx-QPIHPNNM
(2.17±0.61, n=18) binds greater to the adenomas when compared to the control peptide FITC-Ahx-GGGAGGGA (1.14±0.15, n=7).
The mean of each group is represented by a horizontal black line with one standard deviation from the mean displayed. Non-parametric Mann-
Whitney independent samples analysis demonstrates target peptide binds more significantly than control, p,0.01.
doi:10.1371/journal.pone.0017384.g004
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PLoS ONE | www.plosone.org 5 March 2011 | Volume 6 | Issue 3 | e17384Figure 5. Confocal microscopy images showing binding of fluorescence-labeled peptide to colon adenomas. Biopsies were taken after
in vivo administration via the endoscope of the FITC-Ahx-QPIHPNNM target peptide (A) or the FITC-Ahx-GGGAGGGA control peptide (B) and
subsequently imaged. Scale bar, 25 mm.
doi:10.1371/journal.pone.0017384.g005
Figure 6. Wide-field and confocal images of excised adenomas incubated with peptide ex vivo. (A) Two polyps visualized endoscopically
ex vivo under conventional white light illumination. (B) Ex vivo study shows preferential binding of the fluorescent-labeled target peptide FITC-Ahx-
QPIHPNNM compared to the control peptide FITC-Ahx-GGGAGGGA on excised colon. Corresponding representative confocal microscopy images
showing increased binding to the adenoma incubated with (C) target peptide when compared to (D) the control. A target to control peptide binding
ratio was calculated as 2.5160.59 (s.d.) for the excised adenoma pairs. Scale bar, 25 mm.
doi:10.1371/journal.pone.0017384.g006
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inability of the QPIHPNNM peptide to detect the minimally
raised lesions 4 cm proximal from the anal verge as described in
the results, the QPIHPNNM may be utilized to detect dysplastic
tissue from hyperplastic tissue in vivo. Furthermore, the newly
discovered peptide, QPIHPNNM, now provides the opportunity
to improve our optical probes and instruments to optimize wide-
field in vivo lesion detection that can eventually be translated to the
clinic. We have demonstrated the first wide-field fluorescence
binding of a peptide in vivo, showing the advancement and
feasibility of targeted detection of diseased tissue based on tissue
biology rather than anatomical changes in vivo. The technique of in
vivo phage display can also be used to develop additional peptides
to test novel methods of multiple delivery or simultaneous
detection of peptides using this mouse model.
The confocal microscopy results show that the target peptide
specifically binds to dysplastic cells compared to the control
peptide; however, the pattern of target peptide binding suggests
either cell surface or extracellular matrix binding. The
QPIHPNNM molecular target is not known, and the sequence
does not show full homology to any known receptor ligands. The
QPIHPNNM peptide does have partial homology to the Ep300
protein (QP**PNNM) and an undefined cell adhesion molecule-
related/down-regulated by oncogenes precursor (transmembrane
protein, QPIHP), with the latter suspected to be involved in the
development of colorectal tumors [40,41].
Various attempts to design control peptides for target peptide
validation reported include amino acid replacement [42,43],
incorporation of an unrelated peptide sequenced during panning
[44], and peptide scrambling. During the four rounds of T7 phage
library panning in the reported experiment, unrelated peptides
having the same length (8-mer) as the target peptide identified
were not found. Peptide scrambling or amino acid replacement
are most commonly implemented if the binding properties of
individual amino acids is known. Since no structural and binding
site information for the target QPIHPNNM peptide is known,
efforts for designing a scrambled peptide or peptide with altered
amino acids were not attempted. In short peptides (,10 mer), it
has been reported that only few amino acids (2–3) have a
significant role in binding, and these kinds of short peptides can
show some binding even after being scrambled [45]. The nature of
the peptide (i.e., net charge, hydrophobicity, hydrophilicity) can
also determine the fate of the binding. Removing functional
groups and neutralizing charge on a control peptide have been
previously used to demonstrate specific binding of the target
peptide [46,47]. Taking this information into account, we
designed our control peptide (GGGAGGGA) to contain the same
59-FITC fluorophore, Ahx linker, and number of amino acids
compared to the target peptide.
To the best of our knowledge, this is the first study to use a
mouse model that mimics the progression of human colon cancer
to demonstrate the use of fluorescence-labeled peptides to identify
and localize dysplasia in wide-field endoscopy. This approach can
be generalized to other mouse models for studying cancer
development in organs accessible though microendoscopic instru-
ments and ultimately to clinical detection and localization in
human disease.
Materials and Methods
T7 Library construction
The T7 library was constructed with the T7Select 10-3b vector
as reported in the T7Select System Manual (Novagen, Gibbstown,
NJ). Briefly, random oligonucleotide insert DNA for the X18
library was synthesized as follows: 59-AAC TGC AAG CTT TTA-
(MNN)18-ACC ACC ACC AGA ATT CGG ATC CCC GAG
CAT-39 (where N represents an equi-molar ratio of each
nucleotide and M is an equi-molar ratio of adenine and cytosine).
The amino acid translation of the complementary nucleotide
sequence is: MLGDPNSGGGX18. The insert DNA was incubated
with a complementary extension primer (59-ATG CTC GGG
GAT CCG AAT TCTGGT-39), Klenow enzyme (New England
Biolabs, Beverly, MA), and deoxyribonucleotide triphosphates
(Novagen) to form the complementary DNA strand. This was
digested with EcoR1 and HindIII restriction endonucleases (New
England Biolabs). Following phenol/chloroform extraction and
ethanol precipitation, the purified fragments were ligated into
predigested T7Select 10-3b vector by T4 DNA ligase (Novagen).
The ligation reaction was incubated at 16uC, subjected to in vitro
packaging, and titered to determine the number of plaque forming
units (pfu). The remaining solution was amplified in isopropyl b-D-
1-thiogalactopyranoside (IPTG)-induced BLT5615 until lysis. The
lysate was titered and stored at 280uC in glycerol.
Mouse models
Mice were cared for under the approval of the University
Committee on the Use and Care of Animals, University of
Michigan (UCUCA, Approved protocol 09881). The genetically
engineered mouse model (CPC;Apc) that produce adenomatous
polyps are mice containing Cre recombinase under the control of
the Cdx2 promoter (CDX2P-9.5NLS-Cre) and a floxed allele of the
APC gene [12]. This somatic mutation in an Apc allele, which leads
to a truncated Apc protein, causes the development of adenomas in
the distal colon as early as 10 weeks. Mice exhibiting hyperplastic
colon epithelium (hyperplastic Kras) were generated by breeding
mice with mutant Kras allele whose transcription is prevented by a
stop element flanked by LoxP recombination sites (Kras
LSL-G12D/+)
[48,49] with transgenic mice expressing Cre in the epithelial cells
of a significant fraction of crypts of the terminal ileum, cecum and
colon (CDX2P9.5-G22Cre) [50]. All mice were housed in specific
pathogen-free conditions and supplied water ad libitum throughout
the study.
In vivo phage panning procedure
A 9 month old CPC;Apc mouse was injected via tail vein with
1610
11 pfu of the parent T7-18mer library. The library was
allowed to circulate for 10 min, after which the mouse was
euthanized and organs were harvested and kept on ice. The bound
phages were recovered by homogenizing each tissue or organ
(colon adenomas, normal colonic mucosa) (Bio-gen Pro 200) in
DMEM-PI (Dulbecco’s Modified Eagle Medium plus protease
inhibitors: 1 mM phenylmethanesulfonylfluoride (PMSF), 20 mg/
mL aprotinin, and 1 mg/mL leupeptin) [36,37]. The tissue samples
were washed 36 with ice-cold washing medium (DMEM-PI
containing 1% bovine serum albumin), centrifuging for 5 min at
3000 rpm between each wash. After the last wash, freshly starved
bacteria were added to each tissue homogenate and incubated for
30 min at room temperature (RT). Pre-warmed Luria-Bertani
(LB) medium with carbenicillin (50 mg/mL) was then added to the
bacteria-homogenate solution and incubated another 30 min at
RT. The supernatant was recovered after centrifugation and
titered to determine the number of bound phage within each tissue
tested. This procedure constituted one round of panning. After
two rounds of panning, the recovered phages that bound to the
colon adenomas were cleared twice: once against a homogenized
tissue cocktail consisting of colon, kidney, liver and heart and a
second time against normal murine colon. A total of four rounds of
phage panning were performed, with amplification of the
Fluorescence Detection of Murine Colon Dysplasia
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number (1610
11 pfu) was kept constant for each round of
panning. All T7 DNA was sequenced per Novagen’s suggested
protocol using a DNA sequencer (Applied Biosystems, 3730XL
DNA Analyzer, UM DNA Core). The number of phages bound to
each organ or tissue was calculated as the output pfu/(input
pfu6tissue mass).
Peptide synthesis
The peptides were synthesized using standard Fmoc-chemistry
by solid phase synthesis [51]. To ensure the phage and synthetic
peptide were expressed with the same orientation, the candidate
peptide was synthesized with 59-fluorescein isothiocyanate (FITC)
attached to the amino terminus of the peptide via amino hexanoic
acid linker (Ahx). Deprotection and cleavage of the peptides were
achieved by treatment with a cleavage cocktail of trifluoroacetic
acid (TFA)/Tri-isopropylsilane/water (9.5/0.25/0.25, v/v/v) at
RT for 3–4 hours. After cleavage of the product from the resin,
the peptides were purified by preparative-HPLC using a water
(0.1% TFA)-acetonitrile (0.1%TFA) gradient (2–33% acetonitrile
over 31 min) (Waters Breeze HPLC, Milford, MA). The peptides
were characterized by an ESI mass spectrometer (Micromass LCT
Time-of-Flight mass spectrometer with Electrospray, target
peptide (FITC-Ahx-QPIHPNNM) mass (Calc. 1451.89, Obs.
1451.7 [M+H]
+)). The purity (.95%) of the compound was
confirmed by analytical HPLC on a C18 column. As the side
chains of amino acids can have significant roles in binding with
their targets, a control peptide containing Gly and Ala
(GGGAGGGA), which does not have any functional groups on
the amino acid side chains, was synthesized using same methods
(control peptide (FITC-Ahx-GGGAGGGA) mass (Calc. 1004.08
Obs. 1004.4 [M+H]
+)). All peptides were reconstituted in 16
phosphate buffered saline (PBS) at 500 mM and further diluted in
16PBS as necessary.
Small animal endoscopy and peptide administration
Prior to peptide administration, the colon was prepped using a
tap water lavage. Using a small animal endoscope (Karl Storz
Veterinary Endoscopy, Goleta, CA) with a 3Fr instrument channel
for performing biopsy, adenomas suitable for peptide administra-
tion were located, and the colon was rinsed with water until all
mucous was removed [52]. An adenoma was determined not
suitable for peptide administration if the adenoma was large
enough (approximately .4 mm) to make navigation with the
animal endoscope difficult, as peptide delivery and washing would
be inconsistent. Adenomas from approximately 0.5–4 mm that
were not covered in debris, including stool and mucous, were
included in the study.
The fluorescence-labeled peptide was delivered at a concentra-
tion of 100 mMi n1 6PBS through an instrument channel. During
peptide administration, approximately 1 mL of peptide was
delivered to the lower 4 cm of colon in each mouse tested. The
peptide was allowed to incubate for 5 min after which the colon
was cleansed 36with a tap water to remove the unbound peptide.
Prior to imaging, the colon was inspected for residual peptide
solution, and when clean, the colon was insufflated with air and
imaged. Fluorescence excitation in the spectral regime from 450 to
475 nm was produced with a bandpass filter that can be manually
switched to the optical path of a 175 W Nova Xenon light source
and was delivered to the endoscope via a 3 mm diameter fluid
light cable (250 cm length). Fluorescence images were collected
using a 510 nm long-pass filter to block the excitation light and
was detected with a 3-chip color camera with an integrated
parfocal zoom lens. Real time video was recorded via firewire
connected to a pc. Adenomas in CPC;Apc mice developing distal
colonic adenomas (QPIHPNNM n=6 mice having n=18
adenomas; GGGAGGGA n=4 mice having n=7 adenomas) in
addition to Cre recombinase negative littermate controls (QPIHP-
NNM n=2 mice) and hyperplastic Kras mice (QPIHPNNM n=3
mice) were imaged with both white light and fluorescence
endoscopy. The CPC;Apc mice imaged using fluorescence
endoscopy ranged in age from 3 to 5 months.
Fluorescent image analysis
Videos collected during endoscopy were exported as .avi video
files and converted into sequential .png images using Apple
QuickTime. Consecutive white light and fluorescence images for
each adenoma analyzed were imported into NIH Image J. The
white light image was utilized to draw a region of interest (ROI)
around the adenoma or adjacent normal appearing colonic
mucosa which was then superimposed onto the fluorescent image
(Fig. S2). Mean values were calculated for each ROI, and an
adenoma/normal colon, or a target to background ratio (T/B),
value was then calculated for each adenoma. Target to
background ratios were not calculated for Cre recombinase
negative littermate control mice or hyperplastic Kras mice, because
these mice were devoid of adenomas.
Ex vivo Peptide Binding
Adenomas from CPC;Apc mice (n=3 mice, 5 adenoma pairs)
were excised and washed 36 in PBS. The adenomas were
incubated in 100 mM peptide solution for 5 min and subsequently
washed 36 with 16 PBS. Adenomas were grossly imaged using
the small animal endoscope to view binding to the adenoma as a
whole. Pairs of adenomas (one candidate, one control) were
imaged at a time to allow for the calculation of a target peptide to
control peptide binding ratio for each pair analyzed. An average
binding ratio was calculated 6 one standard deviation. A similar
procedure to determine mean values for image analysis was
followed for the ex vivo adenomas as described above for the in vivo
adenomas.
Confocal Fluorescence Imaging
Preferential binding of the target peptide compared to the
control peptide on adenomatous polyps was confirmed with
confocal microscopy after both in vivo and ex vivo testing. From the
in vivo experiment, a biopsy was taken after 59-FITC-labeled
peptide administration in vivo, incubated in 1 mg/mL Hoechst dye
for 5 min to stain living nuclei, rinsed 36 with 16 PBS and
imaged on a Leica TCS SP5 Microscope (Leica Microsystems,
Bannockburn, IL). From the ex vivo experiment, excised adenomas
incubated with peptide ex vivo were subsequently incubated in
1 mg/mL Hoechst dye for 5 min to stain living nuclei, rinsed 36
with 16 PBS and imaged on an Olympus FluoView 500 laser
scanning confocal microscope (Olympus Corp, Tokyo, Japan).
Statistics
All results are shown as mean 6 one standard deviation. A non-
parametric Mann-Whitney Independent Samples test was per-
formed to determine statistical significance which was defined as
p,0.05 between target and control peptide binding to colonic
adenomas (PASW Statistics 18, Chicago, IL).
Histology
All tissue was fixed in phosphate-buffered formalin for 24 hours,
paraffin-embedded and sectioned into 10 mm thin slices and
stained with hematoxylin and eosin (H&E). Histological images
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Microimaging, Inc. Thornwood, NY).
Supporting Information
Figure S1 Preliminary fluorescent peptide binding to
human surgical specimens of non-neoplastic or neoplas-
tic human colon tissue showing QPIHPNNM binds to
dysplastic adenoma but not to normal tissue. The
GGGAGGGA control peptide displayed minimal binding to
normal colon tissue from the same patient. Scale bar 20 mm.
(TIF)
Figure S2 The region of interest (ROI) for each polyp
was selected using a series of image frames exported
upon conversion from .avi video file to serial .png
images using Apple QuickTime Player. The Storz small
animal endoscope has an excitation filter wheel that can be rotated
from the fluorescence excitation filter of 450–475 nm to no
excitation filter which produces an image similar to the wide-field
white light view when the filters are removed from the endoscope.
The image produced when no excitation filter is selected (referred
to as ‘‘filtered white light’’) is still subject to the emission filter of
510–700 nm that is positioned in front of the camera, and is,
therefore, dimmer than the white light images shown in Fig. 2.
Using the filtered white light image (Fig. S2A), a region of interest
around the entire adenoma (yellow polygon) was drawn using the
polygon selection tool in the NIH ImageJ software. This ROI was
then superimposed onto the fluorescence image (Fig. S2B) taken
within ten frames of video. The example shown in Fig. S2 uses
images (A) filtered white light and (B) fluorescence as the exported
.png frames. The ROI for the adjacent suspected normal colon
tissue (white polygon) was chosen using the same method.
(TIF)
Text S1 Preliminary experiments testing for QPIHP-
NNM binding to human surgical specimens of colon
adenomas have been performed.
(DOCX)
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